Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions (PHOTOPAC)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to evaluate the safety and efficacy of preparing a vessel with photoablation with Spectranetics CVX-300® Excimer laser and laser catheters prior to local Paclitaxel delivery compared to local Paclitaxel delivery without initial photoablation
| Condition | Intervention |
|---|---|
|
Restenosis |
Device: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions |
- Target Lesion Percent Stenosis [ Time Frame: at 1 Year ] [ Designated as safety issue: No ]Target Lesion Percent Stenosis at 1 Year: Defined as the narrowest point of the target lesion divided by the estimated native vessel diameter at that location as determined by the angiographic core lab.
- Procedural Success [ Time Frame: at 1 year ] [ Designated as safety issue: Yes ]
Defined as ≤ 30% residual stenosis following the procedure at the target lesion, without periprocedural complications, as determined by the angiographic core lab.
Major Adverse Event Rate at 30 Days and 1 Year: Defined as, major unplanned amputation of the treated limb, all-cause mortality within 1 year of the index procedure or clinically-driven target vessel revascularization within 30 days and 1 year of the index procedure.
| Estimated Enrollment: | 50 |
| Study Start Date: | April 2011 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Laser atherectomy and drug-coated balloon
Laser atherectomy and Paclitaxel-coated balloon angioplasty in treatment of instent lesions of femoropopliteal arteries
|
Device: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems
comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
|
|
Active Comparator: Drug eluting Ballon PTA
Paclitaxel-coated balloon angioplasty
|
Device: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems
comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Subject must meet all of the following general inclusion criteria.
- Has a Rutherford Clinical Category Score of 1 - 5.
- Is willing and capable of complying with all follow-up evaluations at the specified times.
- Is ≥ 18 years old.
- Provides written informed consent prior to study specific procedures.
Exclusion Criteria:
The subject must not meet any of the following general exclusion criteria.
- Has contraindications listed in any study device IFUs.
- Has a contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs or any other drug anticipated to be used.
- Has a hypersensitivity to contrast material that cannot be adequately pretreated.
- Has known hypersensitivity to treatment device materials including Paclitaxel. Has known uncontrollable hypercoagulable condition, or refuses blood transfusion.
6. Has life expectancy of less than 12 months. 7. Is pregnant, of childbearing potential not taking adequate contraceptives, or nursing.
8. Has surgical or endovascular procedure of the target vessel within 14 days prior to the index procedure.
9. Has any planned surgical intervention (requiring hospitalization) or endovascular procedure within 30 days after the index procedure.
10. Is currently participating in an investigational drug or another device study that may clinically interfere with the study outcomes.
11. Any co-morbid condition that in the judgment of the physician precludes safe percutaneous intervention.
12. Has had a previous peripheral bypass affecting the target vessel. 13. Has chronic renal insufficiency with creatinine > 2.5 mg/L (except patients under chronic renal replacement therapy).
14. Is unable or unwilling to receive dual anti-platelet therapy. 15. Equipment is unavailable to fulfill study treatments.
Contacts and Locations More Information
No publications provided
| Responsible Party: | Prof. Dr. Thomas Zeller, Herz-Zentrum Bad Krozingen |
| ClinicalTrials.gov Identifier: | NCT01298947 History of Changes |
| Other Study ID Numbers: | PHOTOPAC |
| Study First Received: | February 17, 2011 |
| Last Updated: | February 18, 2011 |
| Health Authority: | Germany: Ethics Commission |
Keywords provided by Herz-Zentrums Bad Krozingen:
|
Photoablative Atherectomy Paclitaxel-Coated Balloon Instent Femoro-popliteal Obstructions |
Additional relevant MeSH terms:
|
Paclitaxel Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Antineoplastic Agents, Phytogenic Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 21, 2013